alpha-chymotrypsin and Mandibular-Diseases

This article introduces the combined application of vacuum sealing drainage (VSD) and chymotrypsin in the treatment of post-operative mandibular osteomyelitis. The lesion was washed by chymotrypsin (4000U) and saline (500 ml). VSD is effective in the treatment of traumatic mandibular osteomyelitis. This study investigates the effect of VSD combined with chymotrypsin in the treatment of patients with osteomyelitis after mandibular trauma. It is proved that it has a good effect in ensuring drainage, controlling infection and retaining internal fixation, and can create a good environment for fracture healing.. 下颌骨创伤后骨髓炎的治疗以手术和药物联合治疗为主。本文介绍采用封闭负压引流技术（vacuum sealing drainage，VSD）为主的病灶清理术，术后同时行4 000 U糜蛋白酶+500 ml生理盐水持续冲洗的治疗方法。初步探讨VSD联合糜蛋白酶在下颌骨创伤后骨髓炎病例中的应用效果，证实其对保证引流、控制感染、保留内固定有良好作用并可为骨折愈合创造良好环境。以期为下颌骨创伤后骨髓炎的有效治疗提供更简便有效的新方法。.

Topics: Chymotrypsin; Combined Modality Therapy; Drainage; Fracture Fixation, Internal; Fracture Healing; Fractures, Bone; Humans; Mandibular Diseases; Mandibular Injuries; Negative-Pressure Wound Therapy; Osteomyelitis; Vacuum

Recent evidence suggests that the proliferative cells of idiopathic histiocytosis may be derived from Langerhans cells. In this study, antisera to S-100 protein, HLA-DR (la-like) antigen, muramidase, and alpha 1-antichymotrypsin were tested on formalin-fixed, paraffin-embedded tissue from nine cases of idiopathic histiocytosis using an immunoperoxidase technique. Tumor cells were positive for S-100 protein and HLA-DR antigen but negative for muramidase and alpha 1-antichymotrypsin. Mononuclear phagocytes were positive for HLA-DR antigen, muramidase, and alpha 1-antichymotrypsin but negative for S-100 protein. The immunohistochemical staining pattern of the tumor cells in these cases of idiopathic histiocytosis is similar to that seen for normal Langerhans cells. When these results are coupled with electron microscopic and histochemical data, it would appear that the origin of cells in idiopathic histiocytosis is from the Langerhans cell or its precursor. Thus, this condition might be better designated "Langerhans cell disease."

Topics: alpha 1-Antichymotrypsin; Chymotrypsin; Histiocytosis, Langerhans-Cell; Histocompatibility Antigens Class II; HLA-DR Antigens; Humans; Immunoenzyme Techniques; Langerhans Cells; Mandibular Diseases; Maxillary Diseases; Muramidase; Phagocytes; S100 Proteins; Staining and Labeling